Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 7Neoplasms 3Liver Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Stable Metastatic Colorectal Cancer 1Meningioma 1Melanoma 1MCRC 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Metastases 1Leiomyosarcoma 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × regorafenib × Clear all
NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Teclison Ltd.

Phase 2 Recruiting
110 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡